3.2. General Procedure for the Synthesis of [RhCl(cod)(NHC)] Complexes
Starting from [Rh(cod)X]
2 (X = Cl
–, OH
–) and the appropriate 1,3-diaryl-imidazoli-um/imidazolinium salts the corresponding rhodium complexes
1–
4, were prepared in 58–88% yield (
Scheme 1).
Method A: To a solution of 0.88 mmol of the imidazolium/imidazolinium salt in 30 mL of toluene were added 0.44 mmol of [RhCl(cod)]2 and 8.88 mmol of K2CO3 in one portion. The mixture was stirred at 70 °C for 3–24 h (followed by TLC). After removal of the solvent the product was purified by passing through a short silica column in dichloromethane:ethyl acetate = 1:1 as solvent. The coloured fraction of the complex was collected, evaporated to dryness, and the yellow solid was vacuum-dried, characterized by 1H, 13C NMR, and HR ESI-MS.
Method B: To a solution of 0.88 mmol of the imidazolium/imidazolinium salt in 30 mL of toluene was added 0.44 of 0.44 mmol of [Rh(OH)(cod)]2 and the mixture was stirred at 70 °C for the required time (followed by TLC). After removal of the solvent the product was purified by passing through a short silica column in dichloromethane:ethyl acetate = 1:1 as solvent, and the complex was isolated and characterized as in Method A.
Chloro(η4-1,5-cyclooctadiene)(1,3-dimesitylimidazole-2-ylidene)rhodium(I), [RhCl(cod)(IMes)] (1). 302 mg (0.888 mmol) IMes HCl, 220 mg (0.444 mmol) [RhCl(cod)]2, 1228 mg (8.88 mmol) K2CO3, 3 h, yield of 1: A) 345 mg (0.627 mmol) 71%; B) 399 mg (0.725 mmol), 83%. 1H NMR (360 MHz, CD2Cl2) δ/ppm: 7.12–7.11 (m, 4H, HAr), 7.04 (s, 2H, NCH), 4.48 (br, 2H, Hcod), 3.38 (br, 2H, Hcod), 2.46–2.42 (m, 12H, Me), 2.18 (s, 6H, Me), 1.92–1.89 (m, 4H, Hcod), 1.63–1.59 (m, 4H, Hcod); 13C{1H} NMR (CD2Cl2), δ/ppm: 183.2 (d, 1JRh–C = 52.3 Hz); 138.6; 137.4; 136.5; 134.5; 129.3; 128.3; 123.7; 95.7 (d, 1JRh–C = 7.2 Hz); 68.1 (d, 1JRh-C = 14.3 Hz); 32.6; 28.3; 20.8; 19.5; 17.9. MS(ESI), positive mode, in MeOH, m/z for 1, [M]+ (C29H36N2Rh), calculated: 515.1928, found: 515.1928.
Chloro(ƞ4-1,5-cyclooctadiene)(1,3-dimesitylimidazolidin-2-ylidene)rhodium(I), [RhCl(cod)(SIMes)] (2). 304 mg (0.888 mmol) SIMes HCl, 220 mg (0.444 mmol) [RhCl(cod)]2, 1228 mg (8.88 mmol) K2CO3, 22 h, yield of 2: A) 350 mg (0.632 mmol), 71%, B) 428 mg (0.773 mmol), 88%. 1H NMR (360 MHz, CD2Cl2) δ/ppm: 7.09–7.06 (m, 4H, HAr), 4.43 (br, 2H, Hcod), 3.89 (br, 4H, NCH2), 3.46 (br, 2H, Hcod), 2.62 (s, 6H, Me), 2.41–2.38 (m, 12H, Me), 1.85–1.80 (m, 4H, Hcod), 1.64–1.55 (m, 4H, Hcod);13C{1H} NMR (90 MHz, CD2Cl2), δ/ppm: 212.4 (d, 1JRh–C = 48.4 Hz); 138.2; 137.7; 136.6; 135.4; 129.6; 128.5; 96.8 (d,1JRh–C= 6.4 Hz); 67.8 (d, 1JRh–C = 14.3 Hz); 51.47; 32.6; 28.1; 20.8; 19.7; 18.2. MS(ESI), positive mode, in MeOH, m/z for 2, [M]+ (C29H38N2Rh), calculated: 517.2085, found: 517.2085.
Chloro(ƞ4-1,5-cyclooctadiene)(1,3-bis(2,6-diisopropylphenylimidazol)-2-ylidene)rhodium(I), [Rh(Cl)(cod)(IPr)] (3). 378 mg (0.888 mmol) IPr HCl, 220 mg (0.444 mmol) [RhCl(cod)]2, 1228 mg (8.88 mmol) K2CO3, 21 h, yield of 3: A) 494 mg (0.777 mmol), 88%; B) 389 mg (0.612 mmol), 69%. 1H NMR (360 MHz, dmso-d6) δ/ppm: 7.62 (s, 2H, NCH), 7.54 (t, J = 7.7 Hz, 2H, HAr), 7.39 (br, 4H, HAr), 4.33 (br, 2H, Hcod), 3.51 (br, 2H, CH(CH3)2), 3.23 (s, 2H, Hcod), 2.35–2.31 (br, 2H, CH(CH3)2), 1.71–1.27 (m, 8H, Hcod +12H, CH(CH3)2), 1.06 (d, J = 6.8 Hz, 12H, CH(CH3)2);13C{1H} NMR (90 MHz, CDCl3), δ/ppm: 186.1 (d, 1JRh–C = 52.2 Hz); 147.9; 145.3; 136.4; 129.8; 124.6; 122.9; 96.4 (d, 1JRh–C = 7.2 Hz); 67.8 (d, 1JRh–C = 14.4 Hz); 32.7; 28.8; 28.3; 26.6; 22.8. MS(ESI), positive mode, in MeOH, m/z for 3, [M]+ (C35H48N2Rh), calculated: 599.2867, found: 599.2867.
Chloro(ƞ4-1,5-cyclooctadiene)(1,3-bis(2,6-diisopropylphenylimidazolidin)-2-ylidene)rhodium(I), [RhCl(cod)(SIPr)] (4). 380 mg (0.888 mmol) SIPr HCl, 220 mg (0.444 mmol) [RhCl(cod)]2, 1228 mg (8.88 mmol) K2CO3, 24 h, yield of 4: A) 400 mg (0.627 mmol) 70%, B) 386 mg (0.605 mmol) 68%.1H NMR (360 MHz, C6D6) δ/ppm: 7.31–7.24 (m, 4H, HAr), 7.15 (d, J = 6.8 Hz, 2H, HAr), 4.99 (br, 2H, Hcod), 4.43–3.36 (m, 4H, NCH2), 3.73–3.68 (m, 2H, Hcod), 3.43–3.39 (m, 2H, CH(CH3)2), 3.10–3.03 (m, 2H, CH(CH3)2), 1.82–1.70 (m, 10H, Hcod), 1.45–1.18 (m, 18H, CH(CH3)2), 1.05 (d, J = 6.8 Hz, 6H, CH(CH3)2); 13C{1H} NMR (90 MHz, CDCl2), δ/ppm: 214.9 (d, 1JRh–C = 47.7 Hz); 149.3; 146.4; 136.9; 128.8; 124.8; 123.3; 96.4 (d, 1JRh–C = 7.1 Hz); 67.8 (d, 1JRh–C = 13.9 Hz); 53.4; 32.4; 28.9; 28.6; 27.9; 26.6; 24.0; 22.7. MS(ESI), positive mode, in MeOH, m/z for 4, [M]+ (C35H50N2Rh), calculated: 601.3024, found: 601.3025.